Health Care • Biotechnology: Pharmaceutical Preparations
$16.65 ▼ -0.56
(-3.25%)
MKT CAP: $2.29B • VOL: 960.9K
52W L $12 52W H $19
AUPH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $283.1M | $235.1M | $175.5M |
| YoY Revenue Growth % | +20.4% | +34.0% | — |
| Gross Profit | $250.4M | $206.9M | — |
| Gross Margin % | 88.5% | 88.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $104.9M | -$4.7M | -$91.7M |
| Operating Margin % | 37.1% | -2.0% | -52.2% |
| Net Income (GAAP) | $287.2M | $5.8M | -$78.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $135.7M | $44.4M | -$33.5M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $135.7M | $44.4M | -$33.5M |
| FCF Margin % | 47.9% | 18.9% | -19.1% |
| Return on Invested Capital (ROIC %) | 16.5% | -1.3% | — |
| Cash & Short-Term Equivalents | $80.2M | $83.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $581.3M | $377.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AUPH.